

2015 Regular Session

HOUSE BILL NO. 72

BY REPRESENTATIVE MACK

Prefiled pursuant to Article III, Section 2(A)(4)(b)(i) of the Constitution of Louisiana.

CONTROLLED SUBSTANCES: Adds additional substances to Schedule I of the Uniform Controlled Dangerous Substances Law

1 AN ACT

2 To enact R.S. 40:964(Schedule I)(C)(60 through 63), (E)(10 and 11), and (F)(29 through  
3 42), relative to the Uniform Controlled Dangerous Substances Law; to add certain  
4 substances to Schedule I of the Uniform Controlled Dangerous Substances Law; and  
5 to provide for related matters.

6 Be it enacted by the Legislature of Louisiana:

7 Section 1. R.S. 40:964(Schedule I)(C)(60 through 63), (E)(10 and 11), and (F)(29  
8 through 42) are hereby enacted to read as follows:

9 §964. Composition of schedules

10 Schedules I, II, III, IV, and V shall, unless and until added to pursuant to R.S.  
11 40:962, consist of the following drugs or other substances, by whatever official  
12 name, common or usual name, chemical name, or brand name designated:

13 SCHEDULE I

14 \* \* \*

15 C. Hallucinogenic substances. Unless specifically excepted or unless listed  
16 in another schedule, any material, compound, mixture, or preparation, which  
17 contains any quantity of the following hallucinogenic substances, or which contains  
18 any of their salts, isomers, or salts of isomers, whenever the existence of such salts,  
19 isomers, or salts of isomers is possible within the specific chemical designation, for

1 purposes of this Paragraph only, the term "isomer" includes the optical, position, and  
2 geometric isomers:

3 \* \* \*

4 (60) 4-bromo-2,5-dimethoxyphenethylamine (2C-B)

5 (61) N-(2-methoxybenzyl)-2,5-dimethoxy-4-bromophenethylamine  
6 (25B-NBOMe)

7 (62) 5-(2-methylaminopropyl)benzofuran (5-MAPB)

8 (63) 4-hydroxy-N-methyl-N-isopropyltryptamine (4-Hydroxy-MIPT)

9 \* \* \*

10 E. Stimulants. Unless specifically excepted, or contained within a  
11 pharmaceutical product approved by the United States Federal Food and Drug  
12 Administration, or unless listed in another schedule, any material, compound,  
13 mixture, or preparation which contains any quantity of the following substances  
14 having a stimulant effect on the central nervous system including its salts, isomers,  
15 esters, or ethers and salts of isomers, esters, or ethers whenever the existence of such  
16 salts, isomers, esters, or ethers and salts of isomers, esters, or ethers is possible  
17 within the specific chemical designation:

18 \* \* \*

19 (10) 2-(pyrrolidin-1-yl)-1-(thiophen-2-yl)butan-1-one (Alpha-PBT)

20 (11) 2-(pyrrolidin-1-yl)-1-(thiophen-2-yl)pentan-1-one (Alpha-PVT)

21 F. Synthetic cannabinoids. Unless specifically excepted, or contained within  
22 a pharmaceutical product approved by the United States Food and Drug  
23 Administration, or unless listed in another schedule, any material, compound,  
24 mixture, or preparation, which contains any quantity of a synthetic cannabinoid  
25 found to be in any of the following chemical groups, or any of those groups which  
26 contain any synthetic cannabinoid salts, isomers, salts of isomers, or nitrogen-  
27 heterocyclic analogs, whenever the existence of such salts, isomers, salts of isomers,  
28 or nitrogen-heterocyclic analogs is possible within the specific chemical groups:

29 \* \* \*

1                    (29) methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-  
2 methylbutanoate

3                    (30) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-  
4 indazole-3-carboxamide

5                    (31) N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide

6                    (32) naphthalen-1-yl-1-pentyl-1H-indazole-3-carboxylate

7                    (33) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)-1H-indole-  
8 3-carboxamide

9                    (34) 1-(5-fluoropentyl)N-naphthalen-1-yl)-1H-pyrrolo[3,2-c]pyridine-3-  
10 carboxamide

11                    (35) methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3-methyl-  
12 butanoate

13                    (36) methyl 2-(1-pentyl-1H-indazole-3-carboxamido)-3-methylbutanoate

14                    (37) 1-(5-fluoropentyl)-N-(quinolin-8-yl)-1H-indole-3-carboxamide

15                    (38) N-fenchyl-1-[2-(morpholin-4-yl)ethyl]-7-methoxyindole-3-carboxamide

16                    (39) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-  
17 dimethylbutanoate

18                    (40) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-  
19 dimethylbutanoate

20                    (41) methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-  
21 dimethylbutanoate

22                    (42) naphthalen-1-yl(9-pentyl-9H-carbazol-3-yl)methanone

23                    \*           \*           \*

24                    Section 2. This Act shall become effective upon signature by the governor or, if not  
25 signed by the governor, upon expiration of the time for bills to become law without signature  
26 by the governor, as provided by Article III, Section 18 of the Constitution of Louisiana. If  
27 vetoed by the governor and subsequently approved by the legislature, this Act shall become  
28 effective on the day following such approval.

---

**DIGEST**

The digest printed below was prepared by House Legislative Services. It constitutes no part of the legislative instrument. The keyword, one-liner, abstract, and digest do not constitute part of the law or proof or indicia of legislative intent. [R.S. 1:13(B) and 24:177(E)]

---

HB 72 Original

2015 Regular Session

Mack

**Abstract:** Adds 20 substances to Schedule I of the Uniform Controlled Dangerous Substances Law.

Present law provides for classification of controlled dangerous substances in Schedules I through V.

Proposed law adds 20 substances to the list of Schedule I controlled dangerous substances.

Effective upon signature of governor or lapse of time for gubernatorial action.

(Adds 40:964(Schedule I)(C)(60-63), (E)(10 and 11), and (F)(29-42))